Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)||1506%|
|Revenue Growth (QoQ)|
|Held by Institutions %||91%|
|1 Day Vol Adjusted Return||0.1|
|1 Month Vol Adjusted Return||5.8|
|3 Month Vol Adjusted Return||9.0|
|6 Month Vol Adjusted Return||6.9|
|20 Days SMA Price ZScore||0.9|
|50 Days SMA Price ZScore||1.6|
|12 -26 Days PPO||3.7|
|1 Month Average Short Volume Ratio||46.8|
|1 Day Volume Change ZScore||0.1|
|1 Month Daily Vol||4.6|
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March:
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of a month-long virtual storytelling experience to elevate the diverse voices and faces of the rare disease community and benefit Make-A-Wish Mid-Atlantic and Make-A-Wish Canada. The #RAREis photobooth adds to a global commitment to helping grant the wishes of children with life-threatening rare diseases and provide moments of joy during a challenging time.
For any credit ratings referenced in this publication, please see the ratings tab on the issuer/entity page on www.moodys.com for the most updated credit rating action information and rating history. All rights reserved.CREDIT RATINGS ISSUED BY MOODY'S CREDIT RATINGS AFFILIATES ARE THEIR CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND MATERIALS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY’S (COLLECTIVELY, “PUBLI...
Supernus Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before.
Horizon Therapeutics soundly beat fourth-quarter views after capping off what it called a "breakthrough year" with the launch of a new drug and touting the benefits of a new acquisition.
These are the healthcare stocks with the best value, fastest growth, and most momentum for March 2021.
Horizon Therapeutics is showing rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance